You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Maximizing the VALUE we can deliver to patients through partnerships
Strong and meaningful partnerships have played an important role in establishing our proven track record of successful innovation, our broad pipeline and our expertise in novel modalities.
We have discovered, developed and commercialized paradigm-changing treatments for patients in oncology, ophthalmology, urology, immunology and women’s health. We can also scale up global capabilities quickly, for example, we built a leading oncology franchise in just over a decade.
Our early pipeline is our hub for transformational therapies in emerging fields. We start with a deep understanding of disease biology to identify the most suitable, cutting-edge modalities and treatment opportunities, such as cell and gene therapy, that could be life-changing for patients across many different diseases.
We are already creating expandable platforms and continue to seek deals and investments in capabilities that will propel us and our partners towards delivering value.
For Astellas, each new partnership, collaboration or acquisition is an opportunity to enhance our shared potential and deliver more for patients, faster. We value the experience, science and expertise of our partners and the following testimonials capture our approach to collaboration and prioritization of a shared, inclusive culture where innovation thrives.
Collaboration started on November 23, 2021
“Astellas is a world leader in gene therapies, with several AAV pipeline assets and deep expertise in AAV optimization. Astellas and Dyno also share the ambition of advancing the field of gene therapy more broadly, in particular by using next-generation AAV technology to deliver transformative gene therapies to patients. The strengths of our respective teams and our long term commitment to innovation in gene therapy convinced me this would be a winning combination for bringing outstanding new therapies to patients.”
Dyno’s CEO and Co-founder
*Quote from the press release:
Collaboration started on June 14, 2023
“We are excited to enter into this strategic collaboration with Astellas using our novel E3 ligands which we discovered in-house. We are looking forward to working with Astellas to advance more targeted protein degraders into clinical development."
President and CEO at Cullgen
*Quote from the press release:
Collaboration started on March 23, 2020
“We are excited about the use of our technology to assist Astellas in unlocking the potential of T-cell engagers (TCE) in the treatment of solid tumors, building on the growing proof of concept we have established for our platform. This collaboration with Astellas leverages CytomX’s deep expertise in targeting multiple antibody modalities to the tumor microenvironment. We have achieved two clinical candidate nomination since the start of this collaboration. Such continued momentum toward the potential future IND for the first PROBODY® TCE clinical candidate highlights the benefits of our strategy to create value through both wholly-owned and partnered programs.”
Chief Executive Officer and Chairman
*Quote from the press release:
Acquired on July 11, 2023
“The opportunity to create a world-class entity with the ophthalmology expertise and capabilities of Iveric Bio and the global reach and resources of Astellas is unique and has the potential to benefit patients worldwide suffering from blinding retinal diseases, including geographic atrophy.”
President of Iveric Bio.
Press Release:
If you share our passion for innovation and delivering meaningful value to patients, we would love to hear from you. You can reach us here.